AmgenRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Amgen (AMGN) reported revenue of $10.05B in Q2 2026, with Other Products its largest revenue segment at 24%.
Q3 2016-Q2 2026
Q3 2016-Q2 2026
AmgenLarge-cap biopharma. MariTide: antibody-peptide conjugate combining GLP-1 agonism with GIPR antagonism, monthly or less frequent dosing. Phase 3 readout expected late 2026.
Amgen (AMGN) is a Drug Manufacturers - General company. Large-cap biopharma. MariTide: antibody-peptide conjugate combining GLP-1 agonism with GIPR antagonism, monthly or less frequent dosing. Phase 3 readout expected late 2026. It was founded in 1980, is headquartered in Thousand Oaks, CA and employs about 26,800 people.
As of 2025-Q4, Amgen's revenue breaks down across Other Products (24%), Prolia (12%), Otezla (7%), EVENITY (7%). See the revenue-by-segment chart for the full mix.
Track Amgen's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 21, 2026.
Sterling groups Amgen in the GLP-1 sector, alongside Pfizer (PFE), Roche (RHHBY), AstraZeneca (AZN), Merck & Co. (MRK) and AbbVie (ABBV).
If you are researching Amgen, also look at Pfizer (PFE), Roche (RHHBY) and AstraZeneca (AZN). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.